SALT LAKE CITY, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9,434,999 for the company’s amplification suppressor. This technology blocks detection of contaminants present in the environment that may result in a false positive result and potential misdiagnosis of a patient.
The high sensitivity of molecular diagnostic testing makes it vulnerable to the influence of common environmental contaminants such as Staphylococcus epidermidis, which is widely found on skin and public surfaces. To provide for higher test specificity, Great Basin has developed this “amplification suppressor” strategy that can eliminate detection of Staphylococcus species or any other bacteria environmental contaminant when testing clinical specimens such as blood specimens, nasal swabs, or bronchial lavages from suspected pneumonia. The amplification suppressor is used in the Company’s Staph ID/R Blood Culture Panel and is being utilized in the SA Nasal Screen Test, slated for clinical trial in the first half of 2017, as well as future tests and panels.
“In the molecular diagnostics community, concern that a positive test result is actually indicating an environmental contaminant—as opposed a life-threatening organism—has long been an industry concern,” said Robert D. Jenison, chief technology officer of Great Basin Scientific. “Great Basin’s amplification suppressor strategy assures clinicians receive accurate, actionable results that will define a clear treatment path for these ill patients, and supports the Company’s commitment to deliver some of the industry’s most accurate and fast molecular tests. We’re pleased to receive this patent to further protect our assets and portfolio of unique technology.”
With this patent grant, Great Basin has seven U.S. patents issued and 12 patents pending.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the Company's website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statement regarding events, trends and business prospects, which may affect our future operating results and financial position, including but not limited to statements regarding the commercial launch of the Company’s Shiga Toxin Direct Test and Staph ID/R Panel and such commercial launches aiding in building the Company’s total revenue base, increasing sales per customer figures and reducing seasonality in the Company’s revenue stream. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 31, 2016. These forward-looking statements speak only as of the date hereof, and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.